ABSTRACT Antibodies in the sera of patients with myasthenia gravis are believed to play an important role in the pathogenesis of the disorder. They have recently been shown to accelerate the degradation of acetylcholine receptors in cultured mammalian skeletal muscle and at intact neuromuscular junctions. To elucidate the mechanism of the antibodyaccelerated degradation process, we have prepared cultures in which one set of acetylcholine receptors was exposed to myasthenic inmunoglobulin while a second set of acetylcholine receptors, newly incorporated after exposure to the immunoglobulin, was not. The set of acetylcholine receptors with bound myasthenic immunoglobulin was degraded at 2 to 3 times the normal rate, while the second set of acetylcholine receptors without bound immunoglobulin was degraded at the control rate. This suggests that the binding of antibody from myasthenic patients alters the acetylcholine receptors in some way that causes them to be selected for preferential degradation by the muscle cells. New synthesis and incorporation of the acetylcholine receptors into the surface membrane of cultured skeletal muscle was unaffected by exposure to myasthenic immunoglobulin.
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Myasthenia gravis is a neuromuscular disorder characterized by weakness and fatigability of muscles. Recent evidence indicates that there is a decrease of available acetylcholine (AcCho) receptors at the neuromuscular junctions of myasthenic patients (1) (2) (3) (4) (5) , which accounts for the typical clinical and physiological manifestations of the disorder (6) . The pathogenesis of this abnormality is believed to involve an autoimmune attack directed against AcCho receptors (for reviews see refs. 7 and 8). Sera of most patients with myasthenia gravis contain antibody against AcCho receptor (9) (10) (11) , which is capable of reproducing the basic features of the disease on passive transfer to mice (12, 13) .
We and others have recently reported that immunoglobulin (Ig) from myasthenic patients produces a marked acceleration of the rate of degradation of AcCho receptors of mammalian skeletal muscle in tissue culture (14) (15) (16) . In this investigation, we have examined the interactions between myasthenic Ig and AcCho receptors further in rat muscle cultures. Our experiments were designed to distinguish between two possible effects of myasthenic Ig on receptor degradation: (i) A selective effect on AcCho receptors, with accelerated degradation only of that population of receptors to which antibody is bound, and (ii) a nonselective effect on the muscle cell's AcCho receptor-degrading mechanisms, with accelerated degradation of all AcCho receptors, regardless of the presence of bound antibody.
We have tested this proposition by producing cultures in which one population of AcCho receptors has been exposed directly to myasthenic Ig while a second population in the same cultures has not. The degradation rates of these two populations of receptors have been separately followed.
Using similar methods, we have measured synthesis and incorporation of new AcCho receptors into the surface membrane of cultured skeletal muscle after exposure to myasthenic 1g.
MATERIALS AND METHODS
Tissue Culture. Cultures of rat skeletal muscle were prepared by conventional methods (14, 17 (14, 18, 19) that depends on the specific labeling of the receptors with 125I-labeled a-bungarotoxin (125I-a-BuTx) and the release into the culture medium of radioactive material derived from degraded 125I-a-BuTx-AcCho receptor complexes. Sets Table 1 duplicated the conditions in culture set B. Finally, degradation of the labeled receptors was measured over a 6-to 10-hr period, as described below.
In set B, the cultures were initially exposed to medium containing 10% myasthenic or control Ig for 2 hr. After repeated washing to remove excess Ig, the remaining AcCho receptors were blocked with nonradioactive a-BuTx (0.2 yg/ml for 30 min at 370). This step ensured that none of the AcCho receptors that had been treated with Ig would be labeled by subsequent exposure to 125I-a-BuTx. The cultures were returned to the incubator to allow time (6 hr) for synthesis and incorporation of new AcCho receptors. At the end of this period, the new receptors were labeled by incubation with 125I-a-BuTx and the unbound toxin was removed by washing four times.
At 2-hr intervals the medium was removed for determination of relea~ed radioactivity and fresh medium was added to the culture dishes. The initial 2-hr collection was discarded because of the possibility that it might contain the washout of nonspecifically trapped 125I-a-BuTx, and the degradation rates were determined from subsequent collections. At the end of the 8-or 10-hr collection period, the cultures were extracted with 1% Triton X-100 as described above. Synthesis and Incorporation of AcCho Receptors. We have used a modification of the protocol outlined for set B (Table 1) to measure the synthesis and incorporation of AcCho receptors after exposure of the cultures to control or myasthenic Ig (18, 19) . Groups of culture dishes were preincubated with control human Ig to minimize nonspecific adhesion of the myasthenic Ig This experimental protocol provides sister sets of myotube cultures. In set A, the initially present AcCho receptors were labeled, then treated with Ig. In set B, only the new receptors, which were synthesized and incorporated after exposure to Ig, were labeled. Except for the sequence of labeling, the cultures were treated in strictly parallel fashion. For details see text. (14, 15, 18, 19, 21 
Synthesis and incorporation of AcCho receptors
Exposure of sets of cultures to myasthenic Ig did not alter the number of newly synthesized and incorporated AcCho receptors appearing during 6 hr of incubation, as measured by binding of 125I-a-BuTx ( Table 2 ). The amount of 125I-a-BuTx (cpm) bound to cultures treated with IG from four different myasthenic patients did not differ significantly from the amount bound to control Ig-treated cultures (P > 0.1). This normal rate of synthesis and incorporation of AcCho receptors occurred at the same time that AcCho receptors with bound antibody were being rapidly degraded in parallel sets of cultures.
DISCUSSION
There is now abundant evidence that the decrease of junctional AcCho receptors in myasthenia gravis can be brought about by an antibody-mediated autoimmune process. Several studies have shown that Ig from myasthenic patients accelerates the degradation of AcCho receptors in tissue culture of skeletal muscle (14) (15) (16) . Our recent finding that a similar process occurs at intact neuromuscular junctions (22) suggests that acceleration of AcCho receptor degradation potentially represents an important mechanism in the pathogenesis of human myasthenia gravis.
The process of AcCho receptor degradation is believed to begin with endocytosis of the receptors from the muscle's surface membrane (18, 19) . The ingested receptors undergo proteolysis within the muscle cells and the products of degradation are then released externally, into the surrounding medium. Most studies have followed the release of degradation products of 125I-a-BuTx-AcCho receptor complexes, as an indirect measure of the degradation of AcCho receptors (14-16, 18, 19, 22-24) . The validity of this method has been thoroughly established in previous reports, as well as in the specific circumstances of the present investigation (see Results for details). As yet, the mechanism by which myasthenic Ig accelerates receptor degradation has not been elucidated. In this investigation two alternative hypotheses have been considered: First, Ig might interact directly with the AcCho receptors, presumably by binding to them. In this model, only the population of receptors with bound Ig would be rapidly degraded, while other receptors in the same cultures, but without bound Ig, would be degraded at the normal rate. Second, myasthenic Ig might act at the level of the muscle cell, accelerating its internal mechanisms involved in AcCho receptor degradation. This model would not result in a selective process; in a given culture treated with myasthenic Ig all AcCho receptors should be degraded at the same rapid rate.
Our results clearly indicate that the accelerated degradation induced by myasthenic Ig is a selective process. Only the population of AcCho receptors directly exposed to myasthenic Ig (set A) was rapidly degraded; at the same time, a second population of AcCho receptors in the same cultures, newly incorporated into the muscle membrane after exposure to myasthenic Ig (set B), was degraded at the normal rate. The selectivity of this effect argues for a mechanism involving an interaction of myasthenic Ig with surface AcCho receptors, rather than an accelerating effect on the muscle cells' internal degradative mechanisms. It seems likely that binding of the myasthenic antibody to surface AcCho receptors produces some alteration that results in preferential degradation of the antibody-AcCho receptor complexes. Since binding of other ligands, such as a-BuTx, to AcCho receptors does not result in accelerated degradation (18) , the antibody-receptor complex must have some special property that leads to its selective degradation by the muscle cells. Recent evidence suggests that the critical factor is the ability of antibodies to crosslink the receptors (25) . The accelerated degradation of antibody-bound AcCho receptors may be analogous to the process of "modulation," by which antibodies to surface receptors (antigens) of lymphocytes produce aggregation and subsequent reduction of the receptors (26, 27) . Such interactions between macromolecules and surface receptors may not be limited to the immune system; the action of certain hormones on appropriate receptors results in a similar reduction of surface receptors (28, 29) .
In addition to these studies of degradation, we have also measured the synthesis and incorporation of AcCho receptors appearing during a 6-hr period in cultures exposed to myasthenic Ig. It has previously been reported that cultured skeletal muscle contains a pool of precursor AcCho receptors sufficient for incorporation of new surface receptors for up to 3 hr (19, 30) . When longer periods of incubation are used, as in the present experiment, the total number of new surface receptors measured by binding of '25I-a-BuTx should represent the incorporation of both preformed and newly synthesized receptors. The degradation of receptors synthesized during the 6-hr test period can be ignored for the present purposes, since we have shown it to be equal in cultures treated with myasthenic or controlIg. Our results (Table 2) indicate that the number of receptors appearing after exposure to myasthenic Ig was the same as that after controlIg. Thus, at the same time that degradation ofIg-treated receptors is proceeding at a rapid rate, synthesis and incorporation of new receptors remains unaffected.
In conclusion, our findings have demonstrated that the accelerated degradation of AcCho receptors brought about by myasthenic Ig is a selective process, affecting only receptors directly exposed to the antibody. The surface interaction between antibodies and membrane receptors may represent an important pathogenetic process in human myasthenia gravis, as well as in other autoimmune diseases. Further studies are needed to learn how the antibody-receptor complexes are recognized by the cells.
